Glioma resection is associated with prolonged survival, but neuro-oncological trials have frequently refrained from quantifying the extent of resection. The Response Assessment in Neuro-Oncology (RANO) resect group is an international, multidisciplinary group that aims to standardise research practice by delineating the oncological role of surgery in diffuse adult-type gliomas as defined per WHO 2021 classification. Favourable survival effects of more extensive resection unfold over months to decades depending on the molecular tumour profile. In tumours with a more aggressive natural history, supramaximal resection might correlate with additional survival benefit. Weighing the expected survival benefits of resection as dictated by molecular tumour profiles against clinical factors, including the introduction of neurological deficits, we propose an algorithm to estimate the oncological effects of surgery for newly diagnosed gliomas. The algorithm serves to select patients who might benefit most from extensive resection and to emphasise the relevance of quantifying the extent of resection in clinical trials.

中文翻译：

---

WHO 2021 年分类定义的新诊断弥漫性成人型神经胶质瘤切除术的肿瘤作用：RANO 切除小组的综述


胶质瘤切除术与生存期延长相关，但神经肿瘤学试验经常避免量化切除范围。神经肿瘤学反应评估 （RANO） 切除小组是一个国际性的多学科小组，旨在通过描述 WHO 2021 年分类定义的手术在弥漫性成人型神经胶质瘤中的肿瘤作用来标准化研究实践。更广泛切除的有利生存效果在数月至数十年内显现，具体取决于分子肿瘤特征。在自然病程更具侵袭性的肿瘤中，超最大量切除可能与额外的生存获益相关。根据分子肿瘤概况与临床因素（包括神经功能缺损的引入）权衡切除的预期生存益处，我们提出了一种算法来估计手术对新诊断的神经胶质瘤的肿瘤学影响。该算法用于选择可能从广泛切除中获益最大的患者，并强调在临床试验中量化切除范围的相关性。